The United Sorghum Checkoff Program has announced the first human clinical trial to evaluate whole grain sorghum's health benefits, a milestone in the organization's research efforts.
The landmark study, conducted by the University of Nebraska–Lincoln and co-funded by USCP in partnership with USDA's Agriculture and Food Research Initiative Commodity Board program, will investigate how daily consumption of two sorghum varieties affects insulin resistance, inflammation and gut microbiome composition in adults with obesity.
"This first-of-its-kind human study is a direct result of sorghum producers' commitment to scientific research," said Lanier Dabruzzi, director of nutrition and food innovation at the Sorghum Checkoff. "For years, we've seen promising evidence of sorghum's health benefits in vitro and in animal studies, and now we are taking the critical next step."
The randomized crossover study will also measure changes in body weight, blood pressure, blood lipids and other health markers.
Tim Lust, CEO of the Sorghum Checkoff, said the research has significant market implications.
"This groundbreaking trial is laying the groundwork for sorghum's future," Lust said. "The data will be crucial as we pursue qualified health claims with the FDA and collaborate with food companies on new sorghum-based products that deliver on nutrition and sustainability."
